TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2853397

Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31092088

Group type: EXPERIMENTAL
Intervention: Yale‐Vermont Adversity in Childhood Scale (Y‐VACS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Severity of psychological intimate partner violence and neglect
Number of subjects: 150
Study: 30343209

Group type: EXPERIMENTAL
Intervention: Power training
Number of subjects: 18
Study: 26608067

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg orally twice daily)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 25559355

Group type: EXPERIMENTAL
Intervention: Structured reduced carbohydrate dietary intervention for 12 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Structured low-fat dietary intervention for 12 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All intervention groups combined
Number of subjects: 74
Study: 23885048

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose vitamin D (5000 IU/d)
Number of subjects: 0
Study: 20950224

Group type: EXPERIMENTAL
Intervention: Certoparin 3000 IU daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) 7500 IU twice daily
Number of subjects: 335
Study: 17717057

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 12
Study: 15966203

Group type: EXPERIMENTAL
Intervention: Early mobilization and early feeding (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Group 2)
Number of subjects: 0
Study: 12370595

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (twice a week for 6 weeks)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Brief advice (single session with printed materials and verbal guidance)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 103
Study: 10633965

Group type: EXPERIMENTAL
Intervention: PenInject 2.25 self-injector
Number of subjects: 61
Study: 8948882

Group type: EXPERIMENTAL
Intervention: Videothoracoscopy (VT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Minithoracotomy (MT)
Number of subjects: 45
Study: 2012462

Group type: EXPERIMENTAL
Intervention: High-dose ketoconazole (800 mg/kg per day, orally)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amphotericin B (0.5 mg/kg per day, intravenously)
Number of subjects: 72
Study: 7083079

Group type: EXPERIMENTAL
Intervention: Short-term drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcostal incision
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Peritoneal drainage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gallbladder bile
Number of subjects: 100
Study: 29624123

Group type: EXPERIMENTAL
Intervention: Virtual Hope Box (VHB)
Number of subjects: 117

Group type: COMPARATOR
Intervention: enhanced treatment as usual (eTAU)
Number of subjects: 117
Study: 30153875

Group type: EXPERIMENTAL
Intervention: SMALL spoon (teaspoon)
Number of subjects: 20
Study: 26572168

Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training; 4‐10 × 30‐s all‐out bouts at ∼200% of peak power output)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HIIT (high‐intensity interval training; 4‐7 × 4‐min intervals at ∼90% WPeak)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: STCT (sublactate threshold continuous training; 20‐36 min at ∼65% WPeak)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 29
Study: 25218298

Group type: EXPERIMENTAL
Intervention: Act‐HIB+ViscoGel (50mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Act‐HIB (0.2μg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Act‐HIB (2μg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Act‐HIB (10μg)
Number of subjects: 60
Study: 21852332

Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional forceps biopsy
Number of subjects: 600
Study: 19111477

Group type: EXPERIMENTAL
Intervention: Side-to-side repair with permanent sutures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon-to-bone fixation with 1 metal suture anchor loaded with double sutures
Number of subjects: 0
Study: 16518443

Group type: EXPERIMENTAL
Intervention: Imagine the patient's perspective
Number of subjects: 98

Group type: COMPARATOR
Intervention: Imagine how the caregiver would feel if he or she had cancer
Number of subjects: 98

Group type: COMPARATOR
Intervention: Neutral perspective-taking instructions
Number of subjects: 98

Group type: COMPARATOR
Intervention: Self-report perspective-taking instructions
Number of subjects: 98
Study: 14511998

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (aspirin, 325 mg once daily or ticlopidine, 250 mg twice daily)
Number of subjects: 223
Study: 10867377

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bronchial immunotherapy
Number of subjects: 0
Study: 8862841

Group type: EXPERIMENTAL
Intervention: Electromyography (EMG) localization
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local electrical stimulation localization
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups (EMG and stimulation)
Number of subjects: 12
Study: 1335651

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (SmithKline Beecham Biological), vaccination schedule of 0, 1 and 2 months with a booster at month 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (SmithKline Beecham Biological), vaccination schedule of day 0 and 14 with a booster at month 7
Number of subjects: 0
Study: 6701249

Group type: EXPERIMENTAL
Intervention: Relevant events (target)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Irrelevant events (non-target)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: N200 and frontal negative slow wave
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Exogenous components
Number of subjects: 70
Study: 31236667

Group type: EXPERIMENTAL
Intervention: BAY 94-9027 60 IU/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: rFVIIIFc 60 IU/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BAY 94-9027
Number of subjects: 18

Group type: COMPARATOR
Intervention: rFVIIIFc
Number of subjects: 18
Study: 29785045

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) therapy (50 Hz/500 µs) for 4 weeks, with two weekly sessions lasting 15 minutes each, intensity lower than the motor threshold.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo FES treatment following the same routine as the IG.
Number of subjects: 22
Study: 26946725

Group type: EXPERIMENTAL
Intervention: Ginger-partition moxibustion combined with glucocorticoid (methylprednisolone 24 mg daily, tapering down over 6 weeks)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ginger-partition moxibustion combined with glucocorticoid
Number of subjects: 81

Group type: COMPARATOR
Intervention: Simple oral glucocorticoid (methylprednisolone 24 mg daily, tapering down over 6 weeks)
Number of subjects: 81
Study: 23712600

Group type: EXPERIMENTAL
Intervention: niacin/laropiprant (1000/20 mg daily for 4 weeks and 2000/40 mg daily thereafter)
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 22920599

Group type: EXPERIMENTAL
Intervention: Optimized biventricular pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atrial pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 30
Study: 21504975

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 14
Study: 17913310

Group type: EXPERIMENTAL
Intervention: High dosage trivalent influenza vaccine (60 microg of HA for each component)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed vaccine (15 microg of HA for each component)
Number of subjects: 0
Study: 16275526

Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI for patients with no viable myocardium
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI for patients with viability
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI for patients with only diastolic wall‐motion abnormalities
Number of subjects: 106
Study: 12133142

Group type: EXPERIMENTAL
Intervention: Mailed reminders
Number of subjects: 1641

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1641
Study: 11910662

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 5 mg dydrogesterone
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 10 mg dydrogesterone
Number of subjects: 151
Study: 7772369

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study: 2298969

Group type: EXPERIMENTAL
Intervention: Intralesional cyclosporine administered three times weekly for 4 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle treatment (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intralesional cyclosporine
Number of subjects: 6
Study: 6110570

Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin (250 microgram/hour) for 120 minutes
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin (in vitro)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion (in vitro)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin
Number of subjects: 9
Study: 31504587

Group type: EXPERIMENTAL
Intervention: ceftazidime/avibactam
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: both ceftazidime/avibactam and ceftolozane/tazobactam
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: neither ceftazidime/avibactam nor ceftolozane/tazobactam
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: ceftazidime/avibactam only
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam only
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: XDR isolates
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: ceftazidime/avibactam and ceftolozane/tazobactam
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: non-susceptibility
Number of subjects: 205
Study: 28223373

Group type: EXPERIMENTAL
Intervention: NICU-based interventions (including cognitive behavioral therapy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy interventions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NICU-based interventions
Number of subjects: 12
Study: 23946295

Group type: EXPERIMENTAL
Intervention: Children United with Buddies (CUB) intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study: 23280223

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/d for 12 days)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 20147572

Group type: COMPARATOR
Intervention: Diazepam 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levetiracetam 4000 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Valproic acid 1500 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19931753

Group type: EXPERIMENTAL
Intervention: Enzyme-assisted subcutaneous infusion (EASI) with 1-mL injection of 150 U of human recombinant hyaluronidase, followed by 250 mL D5NS infusion.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard intravenous (IV) access with 20-gauge IV placement and 250-mL maximal-rate IV bolus of normal saline.
Number of subjects: 20
Study: 16412720

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 209
Study: 12941059

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10864908

Group type: EXPERIMENTAL
Intervention: VEGF gene transfer
Number of subjects: 0
Study: 9059944

Group type: EXPERIMENTAL
Intervention: Two injections of inactivated hepatitis A vaccine (25 Units) at 0 and 6 months (group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Three injections of inactivated hepatitis A vaccine (25 Units) at 0, 2, and 6 months (group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 105
Study: 1376903

Group type: EXPERIMENTAL
Intervention: Atrial synchronous pacing (DDD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Activity rate modulated ventricular pacing (VVI,R)
Number of subjects: 17
Study: 3891616

Group type: EXPERIMENTAL
Intervention: Tyrosine supplementation (2.5 g t.i.d.)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control conditions (no tyrosine supplementation)
Number of subjects: 13
Study: 31122717

Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (5 weeks, 6 times per week, 5 sets of 10 repetitions, initial load 50% progressing to 70% of maximum inspiratory pressure)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 29582077

Group type: EXPERIMENTAL
Intervention: e‐cigarette users
Number of subjects: 1357

Group type: COMPARATOR
Intervention: nonusers
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: intervention patients (free tobacco treatment)
Number of subjects: 1357

Group type: COMPARATOR
Intervention: control patients (treatment recommendations)
Number of subjects: 1357
Study: 26748872

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 25285695

Group type: EXPERIMENTAL
Intervention: Pursestring closure
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional primary closure
Number of subjects: 122
Study: 22424519

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 657

Group type: COMPARATOR
Intervention: AVR
Number of subjects: 657
Study: 20143466

Group type: EXPERIMENTAL
Intervention: Preoperative TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1‐14)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Immediate surgery (Control)
Number of subjects: 70
Study: 17911462

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 21
Study: 16086601

Group type: EXPERIMENTAL
Intervention: Cetirizine/pseudoephedrine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 36
Study: 11966889

Group type: EXPERIMENTAL
Intervention: Vital pulp therapy with PGE2 measurement
Number of subjects: 79
Study: 11805612

Group type: EXPERIMENTAL
Intervention: Sygen® treatment (specific dosage and duration not mentioned)
Number of subjects: 760
Study: 9922519

Group type: EXPERIMENTAL
Intervention: Mérieux vaccine, 0.1 ml
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Tokio vaccine, 0.1 ml
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Mérieux vaccine, 0.05 ml
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Tokio vaccine, 0.05 ml
Number of subjects: 600
Study: 7921529

Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 9
Study: 3394886

Group type: EXPERIMENTAL
Intervention: Imipramine treatment for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 0
Study: 30135556

Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR-plus-mirtazapine combination
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Bupropion-plus-escitalopram combination
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Overall odds ratio
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy odds ratio
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Venlafaxine-plus-mirtazapine combination odds ratio
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Bupropion-plus-escitalopram combination odds ratio
Number of subjects: 665
Study: 28454823

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) plus oxygen
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (oxygen alone)
Number of subjects: 78
Study: 26363573

Group type: EXPERIMENTAL
Intervention: Superior plating
Number of subjects: 37

Group type: COMPARATOR
Intervention: Anteroinferior plating
Number of subjects: 37
Study: 23224032

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 104
Study: 21198725

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fluvastatin
Number of subjects: 20
Study: 18451387

Group type: EXPERIMENTAL
Intervention: Five weekly intra-articular injections of sodium hyaluronate
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Three weekly intra-articular injections of sodium hyaluronate followed by two weekly intra-articular injections of saline solution
Number of subjects: 660

Group type: COMPARATOR
Intervention: Five weekly intra-articular injections of saline solution
Number of subjects: 660
Study: 16824849

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GPIIb/IIIa blockade
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Heparin plus planned GPIIb/IIIa blockade
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Provisional drug use
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Randomization to bivalirudin
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Provisional GPIIb/IIIa inhibitor
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 6010
Study: 12585985

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11128891

Group type: EXPERIMENTAL
Intervention: Manipulation of patient information
Number of subjects: 50
Study: 9035467

Group type: EXPERIMENTAL
Intervention: Captopril (Cp)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL) - Hypocalemic patients (CLH)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL) - Normocalemic patients (CLN)
Number of subjects: 43
Study: 1552035

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 29638007

Group type: EXPERIMENTAL
Intervention: Dental anxiety
Number of subjects: 3500
Study: 27999852

Group type: COMPARATOR
Intervention: High-Protein Caloric Restriction (HP; n=12)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-Protein Caloric Restriction combined with Resistance Training (HP+RT; n=14)
Number of subjects: 26
Study: 26289163

Group type: EXPERIMENTAL
Intervention: Chronic seton drainage with oral 6-mercaptopurine (6MP) for one year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-TNF medication with 6MP for one year (seton removal after six weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advancement plasty after eight weeks of seton drainage (under four months anti-TNF and 6MP for one year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 0
Study: 23048177

Group type: EXPERIMENTAL
Intervention: Standard smoking cessation intervention (individual counseling and nicotine replacement therapies)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard smoking cessation intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapies
Number of subjects: 100
Study: 20500849

Group type: EXPERIMENTAL
Intervention: Primary hemiarthroplasty (HA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 80
Study: 19422672

Group type: EXPERIMENTAL
Intervention: Wedge-shaped, bedwide, viscoelastic foam cushion
Number of subjects: 162

Group type: COMPARATOR
Intervention: Ordinary pillow
Number of subjects: 162
Study: 16713840

Group type: EXPERIMENTAL
Intervention: Short-arm radial gutter splint
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sugar tong splint
Number of subjects: 118
Study: 16294574

Group type: EXPERIMENTAL
Intervention: Polymeric membrane dressing (polymem)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antibiotic ointment and dry clean dressing (DCD)
Number of subjects: 50
Study: 11238259

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg
Number of subjects: 785
Study: 9231873

Group type: EXPERIMENTAL
Intervention: Children's recalled pain intensity after 1 day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Children's recalled pain intensity after 1 week
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Anxiety, general memory ability, and pain coping strategies
Number of subjects: 55
Study: 7970434

Group type: EXPERIMENTAL
Intervention: One-point arterial sampling with N-isopropyl-p-[123I]-iodoamphetamine (123I-IMP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional microsphere method (for comparison)
Number of subjects: 14